MiR-210: A potential therapeutic target against radiation-induced enteropathy.

• Hamama S INSERM U-1030 "Molecular Radiotherapy", Institut Gustave Roussy, Villejuif, France; LabEX LERMIT Villejuif, France; Université Paris Sud Paris XI, Le Kremlin Bicêtre, France. Electronic address: saad.hamama@igr.fr.
• Noman MZ INSERM, U753, Laboratoire d'immunologie des Tumeurs Humaines: Interaction Effecteurs Cytotoxiques-Système Tumoral, Institut Gustave-Roussy, Villejuif, France. Electronic address: muhammed-zaeem.noman@igr.fr.
• Gervaz P Geneva University Hospital and Medical School, Geneva, Switzerland. Electronic address: pascal.gervaz@lacolline.ch.
• Delanian S Unité de Radiopathologie, Service Oncologie-Radiothérapie, Hôpital Saint-Louis, APHP, Paris, France. Electronic address: sylvie.delanian@sls.aphp.fr.
• Vozenin MC INSERM U-1030 "Molecular Radiotherapy", Institut Gustave Roussy, Villejuif, France; LabEX LERMIT Villejuif, France; Université Paris Sud Paris XI, Le Kremlin Bicêtre, France; Laboratoire de RadioOncologie, Swiss Cancer Center of Lausanne, CHUV, Lausanne, Switzerland. Electronic address: marie-catherine.vozenin@chuv.ch.

Anti-fibrotic treatment

Pentoxifylline

Radiation enteropathy

Radiation-induced fibrosis

Trolox

microRNA miR-210

Antioxidants

Cells, Cultured

Drug Therapy, Combination

Fibrosis

Humans

Hypoxia

Intestinal Diseases

MicroRNAs

Molecular Targeted Therapy

Myocytes, Smooth Muscle

Pentoxifylline

Platelet Aggregation Inhibitors

RNA

RNA, Mitochondrial

Radiation Injuries

Radiation-Protective Agents

Radiotherapy

alpha-Tocopherol